论文部分内容阅读
目的探讨巴曲酶治疗急性脑梗死的临床疗效及安全性评价。方法 92例6～72 h内急性脑梗死患者随机分为2组,治疗组46例,接受巴曲酶治疗(治疗组),并与同期未接受巴曲酶治疗的46例急性脑梗死患者(对照组)对比研究。分别观察治疗前后改良的爱丁堡+斯堪的那维亚评分。结果①治疗前治疗组的评分平均是(32.98±7.39)分,对照组的评分是(32.32±6.95)分,差异无统计学意义(P>0.05);治疗21 d后两组的评分分别是(16.12±6.28)分和(23.19±6.42)分(<0.01);两组之间具有显著差异。②巴曲酶治疗组无一例并发症发生。结论利用巴曲酶进行急性脑梗死规范化降纤治疗是安全、有效的。
Objective To investigate the clinical efficacy and safety of batroxobin in the treatment of acute cerebral infarction. Methods Ninety-two patients with acute cerebral infarction within 6 ~ 72 h were randomly divided into two groups, 46 in the treatment group receiving batroxobin (treatment group) and 46 patients in the acute cerebral infarction group (untreated with batroxobin) Control group) comparative study. The modified Edinburgh + Scandinavia scores were observed before and after treatment. Results ① The average score of the treatment group before treatment was (32.98 ± 7.39) points, while that of the control group was (32.32 ± 6.95) points, with no significant difference (P> 0.05). After 21 days of treatment, the scores of the two groups were (16.12 ± 6.28) points and (23.19 ± 6.42) points (<0.01). There was a significant difference between the two groups. ② Batroxobin group no complications occurred. Conclusion It is safe and effective to use Batroxobin to standardize the treatment of acute cerebral infarction.